Literature DB >> 6453216

An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.

A d'Hollander, C Delcroix.   

Abstract

A pharmacodynamic model for nondepolarizing neuromuscular blocking agents (NMBA) is developed and tested with different sets of data (NMBA plasma concentration and time evolution of muscular paralysis). This model takes into account the binding of NMBA to the cholinergic motor endplate receptors and thus permits estimation of the apparent equilibrium constant of the NMBA-receptor exchange. The parameters defining the relationship between relative postsynaptic receptor occupation and muscular paralysis can also be determined. The simulated muscular paralysis time curves, calculated for various modes of NMBA administration (loading injection and multiple injections or continuous infusion) are comparable to those observed clinically. As compared to previous NMBA pharmacodynamic models, the model presented in this study utilizes and describes all the main steps between changes in the plasma NMBA concentration and the observed response: pharmacokinetics, ligand-receptor exchanges, and receptor occupation-effect relationship. This model illustrates a general methodology for the study of pharmacokinetic and pharmacodynamic problems.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6453216     DOI: 10.1007/bf01059341

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  28 in total

1.  A study of curare action with an electrical micromethod.

Authors:  L DEL CASTILLO; B KATZ
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-05-07

2.  Clinical neuromuscular pharmacology of AH 8165 D, an azobis-arylimidazo-pyridinium-compound.

Authors:  F T Schuh
Journal:  Anaesthesist       Date:  1975-04       Impact factor: 1.041

3.  Pharmacokinetics of fazadinium in man.

Authors:  P Duvaldestin; D Henzel; M Demetriou; J M Desmonts
Journal:  Br J Anaesth       Date:  1978-08       Impact factor: 9.166

4.  Relation of serum d-tubocurarine concentration to neuromuscular blockade in man.

Authors:  R S Matteo; S Spector; P E Horowitz
Journal:  Anesthesiology       Date:  1974-11       Impact factor: 7.892

5.  Comparison of drug-receptor dissociation constants at the mammalian neuromuscular junction in the presence and absence of halothane.

Authors:  B E Waud; M C Cheng; D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

6.  The fate of pancuronium bromide in man.

Authors:  S Agoston; G A Vermeer; U W Kertsten; D K Meijer
Journal:  Acta Anaesthesiol Scand       Date:  1973       Impact factor: 2.105

7.  Durations of action of d-tubocurarine and gallamine.

Authors:  L F Walts; J B Dillon
Journal:  Anesthesiology       Date:  1968 May-Jun       Impact factor: 7.892

8.  A preliminary investigation of the renal and hepatic excretion of gallamine triethiodide in man.

Authors:  S Agoston; G A Vermeer; U W Kersten; A H Scaf
Journal:  Br J Anaesth       Date:  1978-04       Impact factor: 9.166

9.  The pharmacokinetics of d-tubocurarine in man with and without renal failure.

Authors:  R D Miller; R S Matteo; L Z Benet; Y J Sohn
Journal:  J Pharmacol Exp Ther       Date:  1977-07       Impact factor: 4.030

10.  Clinical pharmacokinetics of pancuronium bromide.

Authors:  A A Somogyi; C A Shanks; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

View more
  5 in total

1.  An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs.

Authors:  J H Proost; J M Wierda; D K Meijer
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

2.  Kinetics of d-tubocurarine disposition and pharmacologic response in rats.

Authors:  A Morino; K Kitamura; K Katayama; M Kakemi; T Koizumi
Journal:  J Pharmacokinet Biopharm       Date:  1983-02

3.  Pharmacokinetic and pharmacodynamic modelling with pancuronium.

Authors:  M A Evans; C A Shanks; K F Brown; E J Triggs
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Analytical model of some pharmacokinetic and pharmacodynamic properties of fazadinium in man.

Authors:  A A d'Hollander; C Delcroix; P Duvaldestin; D Henzel; E Coussaert; J M Desmonts
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Receptor-mediated model relating anticonvulsant effect to brain levels of camazepam in the presence of its active metabolites.

Authors:  A Morino; H Sasaki; H Mukai; M Sugiyama
Journal:  J Pharmacokinet Biopharm       Date:  1986-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.